$1-per-pill alternative to Turing drug gets 'overwhelming' response: Imprimis CEO

Imprimis ($IMMY) CEO Mark Baum says response has been "overwhelming" to his company's $1-per-pill alternative to toxoplasmosis drug Daraprim, from the now-notorious Turing Pharmaceuticals, which raised its pill price to $750 each from $13.50 earlier this year. Report

Suggested Articles

Novartis is taking its MBC campaign to Instagram with a newly launched video series as part of the five-year “Make Your Dialogue Count” effort.

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Leo Pharma's latest "hackathon" brought together scientists and entrepreneurs to find dermatology solutions for people of color.